Metabolic effects of anti-angiogenic therapy in tumors

Biochimie

Volumn 94, Issue 4, 2012, Pages 925-931

  Zulato, Elisabetta ^a   Curtarello, Matteo ^a   Nardo, Giorgia ^a   Indraccolo, Stefano ^a  

^a VENETO INSTITUTE OF ONCOLOGY IOV IRCCS   (Italy)

Author keywords

Angiogenesis; Anti angiogenic therapy; Glycolysis; LKB1 AMPK pathway

Indexed keywords

BEVACIZUMAB; EFLORNITHINE; GLUCOSE; PLACEBO; VATALANIB;

ANTIANGIOGENIC ACTIVITY; ANTIANGIOGENIC THERAPY; APOPTOSIS; BREAST CANCER; CANCER PROGNOSIS; CELL PROLIFERATION; COLORECTAL CANCER; CYTOSTASIS; DISEASE MARKER; ENZYME ACTIVATION; GLIOBLASTOMA; HUMAN; HYPERTENSION; HYPOXIA; KIDNEY CARCINOMA; LUNG CANCER; LUNG NON SMALL CELL CANCER; NONHUMAN; NUTRIENT SUPPLY; OVERALL SURVIVAL; OXIDATIVE PHOSPHORYLATION; PROGRESSION FREE SURVIVAL; PROSTATE CANCER; REVIEW;

ADENYLATE KINASE; ANGIOGENESIS INHIBITORS; ANIMALS; ANTIBODIES, MONOCLONAL, HUMANIZED; CELL HYPOXIA; CLINICAL TRIALS AS TOPIC; ENZYME ACTIVATION; HUMANS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC;

ANIMALIA;

EID: 84857450316     PISSN: 03009084     EISSN: 61831638     Source Type: Journal    
DOI: 10.1016/j.biochi.2012.01.001     Document Type: Review

References (78)

1. V.L. Heath, and R. Bicknell Anticancer strategies involving the vasculature Nat. Rev. Clin. Oncol. 6 2009 395 404
2. B.M. Fenton, S.F. Paoni, and I. Ding Effect of VEGF receptor-2 antibody on vascular function and oxygenation in spontaneous and transplanted tumors Radiother. Oncol. 72 2004 221 230 (Pubitemid 39024597)
3. M. Franco, S. Man, L. Chen, U. Emmenegger, Y. Shaked, A.M. Cheung, A.S. Brown, D.J. Hicklin, F.S. Foster, and R.S. Kerbel Targeted anti-vascular endothelial growth factor receptor-2 therapy leads to short-term and long-term impairment of vascular function and increase in tumor hypoxia Cancer Res. 66 2006 3639 3648
4. F. Winkler, S.V. Kozin, R.T. Tong, S.S. Chae, M.F. Booth, I. Garkavtsev, L. Xu, D.J. Hicklin, D. Fukumura, E. di Tomaso, L.L. Munn, and R.K. Jain Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: role of oxygenation, angiopoietin-1, and matrix metalloproteinases Cancer Cell 6 2004 553 563 (Pubitemid 40017699)
5. A. Grothey, and E. Galanis Targeting angiogenesis: progress with anti-VEGF treatment with large molecules Nat. Rev. Clin. Oncol. 6 2009 507 518
6. R.K. Jain, D.G. Duda, J.W. Clark, and J.S. Loeffler Lessons from phase III clinical trials on anti-VEGF therapy for cancer Nat. Clin. Pract. Oncol. 3 2006 24 40 (Pubitemid 43108832)
7. R.K. Jain, D.G. Duda, C.G. Willett, D.V. Sahani, A.X. Zhu, J.S. Loeffler, T.T. Batchelor, and A.G. Sorensen Biomarkers of response and resistance to antiangiogenic therapy Nat. Rev. Clin. Oncol. 6 2009 327 338
8. H.J. Burstein, Y.H. Chen, L.M. Parker, J. Savoie, J. Younger, I. Kuter, P.D. Ryan, J.E. Garber, H. Chen, S.M. Campos, L.N. Shulman, L.N. Harris, R. Gelman, and E.P. Winer VEGF as a marker for outcome among advanced breast cancer patients receiving anti-VEGF therapy with bevacizumab and vinorelbine chemotherapy Clin. Cancer Res. 14 2008 7871 7877
9. E. Carrillo de Santa Pau, F.C. Arias, E. Caso Pelaez, G.M. Munoz Molina, I. Sanchez Hernandez, I. Muguruza Trueba, R. Moreno Balsalobre, S. Sacristan Lopez, A. Gomez Pinillos, and M. del Val Toledo Lobo Prognostic significance of the expression of vascular endothelial growth factors A, B, C, and D and their receptors R1, R2, and R3 in patients with nonsmall cell lung cancer Cancer 115 2009 1701 1712
10. A. Dowlati, R. Gray, A.B. Sandler, J.H. Schiller, and D.H. Johnson Cell adhesion molecules, vascular endothelial growth factor, and basic fibroblast growth factor in patients with non-small cell lung cancer treated with chemotherapy with or without bevacizumab-an Eastern Cooperative Oncology Group Study Clin. Cancer Res. 14 2008 1407 1412 (Pubitemid 351413922)
11. A.M. Jubb, and A.L. Harris Biomarkers to predict the clinical efficacy of bevacizumab in cancer Lancet Oncol. 11 2010 1172 1183
12. B.P. Schneider, M. Wang, M. Radovich, G.W. Sledge, S. Badve, A. Thor, D.A. Flockhart, B. Hancock, N. Davidson, J. Gralow, M. Dickler, E.A. Perez, M. Cobleigh, T. Shenkier, S. Edgerton, and K.D. Miller Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100 J. Clin. Oncol. 26 2008 4672 4678
13. K.D. Steffensen, M. Waldstrom, I. Brandslund, and A. Jakobsen The relationship of VEGF polymorphisms with serum VEGF levels and progression-free survival in patients with epithelial ovarian cancer Gynecol. Oncol. 117 2010 109 116
14. C.S. Facemire, A.B. Nixon, R. Griffiths, H. Hurwitz, and T.M. Coffman Vascular endothelial growth factor receptor 2 controls blood pressure by regulating nitric oxide synthase expression Hypertension 54 2009 652 658
15. P. Bono, H. Elfving, T. Utriainen, P. Osterlund, T. Saarto, T. Alanko, and H. Joensuu Hypertension and clinical benefit of bevacizumab in the treatment of advanced renal cell carcinoma Ann. Oncol. 20 2009 393 394
16. S.E. Dahlberg, A.B. Sandler, J.R. Brahmer, J.H. Schiller, and D.H. Johnson Clinical course of advanced non-small-cell lung cancer patients experiencing hypertension during treatment with bevacizumab in combination with carboplatin and paclitaxel on ECOG 4599 J. Clin. Oncol. 28 2010 949 954
17. M. Scartozzi, E. Galizia, S. Chiorrini, R. Giampieri, R. Berardi, C. Pierantoni, and S. Cascinu Arterial hypertension correlates with clinical outcome in colorectal cancer patients treated with first-line bevacizumab Ann. Oncol. 20 2009 227 230
18. A.R. Padhani Dynamic contrast-enhanced MRI in clinical oncology: current status and future directions J. Magn. Reson. Imaging 16 2002 407 422 (Pubitemid 35167876)
19. O.M. Hahn, C. Yang, M. Medved, G. Karczmar, E. Kistner, T. Karrison, E. Manchen, M. Mitchell, M.J. Ratain, and W.M. Stadler Dynamic contrast-enhanced magnetic resonance imaging pharmacodynamic biomarker study of sorafenib in metastatic renal carcinoma J. Clin. Oncol. 26 2008 4572 4578
20. A.G. Sorensen, T.T. Batchelor, W.T. Zhang, P.J. Chen, P. Yeo, M. Wang, D. Jennings, P.Y. Wen, J. Lahdenranta, M. Ancukiewicz, E. di Tomaso, D.G. Duda, and R.K. Jain A "vascular normalization index" as potential mechanistic biomarker to predict survival after a single dose of cediranib in recurrent glioblastoma patients Cancer Res. 69 2009 5296 5300
21. A. Salskov, V.S. Tammisetti, J. Grierson, and H. Vesselle FLT: measuring tumor cell proliferation in vivo with positron emission tomography and 3'-deoxy-3'-[18F]fluorothymidine Semin. Nucl. Med. 37 2007 429 439 (Pubitemid 47498262)
22. W. Chen, S. Delaloye, D.H. Silverman, C. Geist, J. Czernin, J. Sayre, N. Satyamurthy, W. Pope, A. Lai, M.E. Phelps, and T. Cloughesy Predicting treatment response of malignant gliomas to bevacizumab and irinotecan by imaging proliferation with [18F] fluorothymidine positron emission tomography: a pilot study J. Clin. Oncol. 25 2007 4714 4721 (Pubitemid 350086472)
23. P.M. Wilson, D. Yang, M.M. Shi, W. Zhang, C. Jacques, J.C. Barret, K. Daneneberg, T. Trarbach, G. Folprecht, G. Meinhardt, H.J. Lenz, Use of intratumoral mRNA expression of genes involved in angiogenesis and HIF1 pathway to predict outcome to VEGFR tyrosine Kinase inhibitor (TKI) in patients enrolled in CONFIRM1 and CONFIRM2, ASCO Annu. Meet. (2008).
24. M.I. Koukourakis, A. Giatromanolaki, E. Sivridis, K.C. Gatter, T. Trarbach, G. Folprecht, M.M. Shi, D. Lebwohl, T. Jalava, D. Laurent, G. Meinhardt, and A.L. Harris Prognostic and predictive role of lactate dehydrogenase 5 expression in colorectal cancer patients treated with PTK787/ZK 222584 (Vatalanib) antiangiogenic therapy Clin. Cancer Res. 17 2011 4892 4900
25. J.R. Hecht, T. Trarbach, J.D. Hainsworth, P. Major, E. Jager, R.A. Wolff, K. Lloyd-Salvant, G. Bodoky, K. Pendergrass, W. Berg, B.L. Chen, T. Jalava, G. Meinhardt, D. Laurent, D. Lebwohl, and D. Kerr Randomized, placebo-controlled, phase III study of first-line oxaliplatin-based chemotherapy plus PTK787/ZK 222584, an oral vascular endothelial growth factor receptor inhibitor, in patients with metastatic colorectal adenocarcinoma J. Clin. Oncol. 29 2011 1997 2003
26. O. Warburg On the origin of cancer cells Science 123 1956 309 314
27. M.G. Vander Heiden, L.C. Cantley, and C.B. Thompson Understanding the warburg effect: the metabolic requirements of cell proliferation Science 324 2009 1029 1033
28. V. Fritz, and L. Fajas Metabolism and proliferation share common regulatory pathways in cancer cells Oncogene 29 2010 4369 4377
29. A.J. Levine, and A.M. Puzio-Kuter The control of the metabolic switch in cancers by oncogenes and tumor suppressor genes Science 330 2010 1340 1344
30. S.S. Gambhir Molecular imaging of cancer with positron emission tomography Nat. Rev. Cancer 2 2002 683 693 (Pubitemid 37328919)
31. H. Shim, C. Dolde, B.C. Lewis, C.S. Wu, G. Dang, R.A. Jungmann, R. Dalla-Favera, and C.V. Dang c-Myc transactivation of LDH-A: implications for tumor metabolism and growth Proc. Natl. Acad. Sci. U S A 94 1997 6658 6663 (Pubitemid 27281920)
32. D.A. Tennant, R.V. Duran, and E. Gottlieb Targeting metabolic transformation for cancer therapy Nat. Rev. Cancer 10 2010 267 277
33. S. Walenta, M. Wetterling, M. Lehrke, G. Schwickert, K. Sundfor, E.K. Rofstad, and W. Mueller-Klieser High lactate levels predict likelihood of metastases, tumor recurrence, and restricted patient survival in human cervical cancers Cancer Res. 60 2000 916 921 (Pubitemid 30129526)
34. R.C. Osthus, H. Shim, S. Kim, Q. Li, R. Reddy, M. Mukherjee, Y. Xu, D. Wonsey, L.A. Lee, and C.V. Dang Deregulation of glucose transporter 1 and glycolytic gene expression by c-Myc J. Biol. Chem. 275 2000 21797 21800 (Pubitemid 30621745)
35. R.J. DeBerardinis, J.J. Lum, G. Hatzivassiliou, and C.B. Thompson The biology of cancer: metabolic reprogramming fuels cell growth and proliferation Cell Metab. 7 2008 11 20
36. W.H. Koppenol, P.L. Bounds, and C.V. Dang Otto warburg's contributions to current concepts of cancer metabolism Nat. Rev. Cancer 11 2011 325 337
37. G.L. Semenza Targeting HIF-1 for cancer therapy Nat. Rev. Cancer 3 2003 721 732 (Pubitemid 37328811)
38. K. Bensaad, A. Tsuruta, M.A. Selak, M.N. Vidal, K. Nakano, R. Bartrons, E. Gottlieb, and K.H. Vousden TIGAR, a p53-inducible regulator of glycolysis and apoptosis Cell 126 2006 107 120 (Pubitemid 44040989)
39. S. Matoba, J.G. Kang, W.D. Patino, A. Wragg, M. Boehm, O. Gavrilova, P.J. Hurley, F. Bunz, and P.M. Hwang p53 regulates mitochondrial respiration Science 312 2006 1650 1653 (Pubitemid 43902663)
40. R.J. DeBerardinis, A. Mancuso, E. Daikhin, I. Nissim, M. Yudkoff, S. Wehrli, and C.B. Thompson Beyond aerobic glycolysis: transformed cells can engage in glutamine metabolism that exceeds the requirement for protein and nucleotide synthesis Proc. Natl. Acad. Sci. U S A 104 2007 19345 19350
41. M. Yuneva, N. Zamboni, P. Oefner, R. Sachidanandam, and Y. Lazebnik Deficiency in glutamine but not glucose induces MYC-dependent apoptosis in human cells J. Cell Biol. 178 2007 93 105 (Pubitemid 47026405)
42. P. Gao, I. Tchernyshyov, T.C. Chang, Y.S. Lee, K. Kita, T. Ochi, K.I. Zeller, A.M. De Marzo, J.E. Van Eyk, J.T. Mendell, and C.V. Dang c-Myc suppression of miR-23a/b enhances mitochondrial glutaminase expression and glutamine metabolism Nature 458 2009 762 765
43. H. Nawashiro, N. Otani, N. Shinomiya, S. Fukui, H. Ooigawa, K. Shima, H. Matsuo, Y. Kanai, and H. Endou L-type amino acid transporter 1 as a potential molecular target in human astrocytic tumors Int. J. Cancer 119 2006 484 492 (Pubitemid 43955699)
44. C. Plathow, and W.A. Weber Tumor cell metabolism imaging J. Nucl. Med. 49 Suppl. 2 2008 43S 63S (Pubitemid 351948036)
45. T. Singhal, T.K. Narayanan, V. Jain, J. Mukherjee, and J. Mantil 11C-L-methionine positron emission tomography in the clinical management of cerebral gliomas Mol. Imaging Biol. 10 2008 1 18
46. J.A. Menendez, and R. Lupu Fatty acid synthase and the lipogenic phenotype in cancer pathogenesis Nat. Rev. Cancer 7 2007 763 777 (Pubitemid 47469806)
47. E. Iorio, D. Mezzanzanica, P. Alberti, F. Spadaro, C. Ramoni, S. D'Ascenzo, D. Millimaggi, A. Pavan, V. Dolo, S. Canevari, and F. Podo Alterations of choline phospholipid metabolism in ovarian tumor progression Cancer Res. 65 2005 9369 9376 (Pubitemid 41508005)
48. E. Iorio, A. Ricci, M. Bagnoli, M.E. Pisanu, G. Castellano, M. Di Vito, E. Venturini, K. Glunde, Z.M. Bhujwalla, D. Mezzanzanica, S. Canevari, and F. Podo Activation of phosphatidylcholine cycle enzymes in human epithelial ovarian cancer cells Cancer Res. 70 2010 2126 2135
49. S. Faivre, G. Demetri, W. Sargent, and E. Raymond Molecular basis for sunitinib efficacy and future clinical development Nat. Rev. Drug Discov. 6 2007 734 745 (Pubitemid 47338181)
50. G. Nardo, E. Favaro, M. Curtarello, L. Moserle, E. Zulato, L. Persano, E. Rossi, G. Esposito, M. Crescenzi, O. Casanovas, U.G. Sattler, W. Mueller-Klieser, B. Biesalski, O. Thews, R. Canese, E. Iorio, P. Zanovello, A. Amadori, and S. Indraccolo Glycolytic phenotype and amp kinase modify the pathologic response of tumor xenografts to vegf neutralization Cancer Res. 2011
51. C.G. Willett, Y. Boucher, E. di Tomaso, D.G. Duda, L.L. Munn, R.T. Tong, D.C. Chung, D.V. Sahani, S.P. Kalva, S.V. Kozin, M. Mino, K.S. Cohen, D.T. Scadden, A.C. Hartford, A.J. Fischman, J.W. Clark, D.P. Ryan, A.X. Zhu, L.S. Blaszkowsky, H.X. Chen, P.C. Shellito, G.Y. Lauwers, and R.K. Jain Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer Nat. Med. 10 2004 145 147 (Pubitemid 38524883)
52. S. Mehta, N.P. Hughes, F.M. Buffa, S.P. Li, R.F. Adams, A. Adwani, N.J. Taylor, N.C. Levitt, A.R. Padhani, A. Makris, and A.L. Harris Assessing early therapeutic response to bevacizumab in primary breast cancer using magnetic resonance imaging and gene expression profiles J. Natl. Cancer Inst. Monogr. 2011 2011 71 74
53. O. Keunen, M. Johansson, A. Oudin, M. Sanzey, S.A. Rahim, F. Fack, F. Thorsen, T. Taxt, M. Bartos, R. Jirik, H. Miletic, J. Wang, D. Stieber, L. Stuhr, I. Moen, C.B. Rygh, R. Bjerkvig, and S.P. Niclou Anti-VEGF treatment reduces blood supply and increases tumor cell invasion in glioblastoma Proc. Natl. Acad. Sci. U S A 108 2011 3749 3754
54. F.A. Howe, S.J. Barton, S.A. Cudlip, M. Stubbs, D.E. Saunders, M. Murphy, P. Wilkins, K.S. Opstad, V.L. Doyle, M.A. McLean, B.A. Bell, and J.R. Griffiths Metabolic profiles of human brain tumors using quantitative in vivo 1H magnetic resonance spectroscopy Magn. Reson. Med. 49 2003 223 232 (Pubitemid 36159858)
55. A. Sreekumar, L.M. Poisson, T.M. Rajendiran, A.P. Khan, Q. Cao, J. Yu, B. Laxman, R. Mehra, R.J. Lonigro, Y. Li, M.K. Nyati, A. Ahsan, S. Kalyana-Sundaram, B. Han, X. Cao, J. Byun, G.S. Omenn, D. Ghosh, S. Pennathur, D.C. Alexander, A. Berger, J.R. Shuster, J.T. Wei, S. Varambally, C. Beecher, and A.M. Chinnaiyan Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression Nature 457 2009 910 914
56. Z.J. Reitman, G. Jin, E.D. Karoly, I. Spasojevic, J. Yang, K.W. Kinzler, Y. He, D.D. Bigner, B. Vogelstein, and H. Yan Profiling the effects of isocitrate dehydrogenase 1 and 2 mutations on the cellular metabolome Proc. Natl. Acad. Sci. U S A 108 2011 3270 3275
57. K.J. Svensson, J.E. Welch, P. Kucharzewska, P. Bengtson, M. Bjurberg, S. Pahlman, G.B. Ten Dam, L. Persson, and M. Belting Hypoxia-mediated induction of the polyamine system provides opportunities for tumor growth inhibition by combined targeting of vascular endothelial growth factor and ornithine decarboxylase Cancer Res. 68 2008 9291 9301
58. A. Alexander, and C.L. Walker The role of LKB1 and AMPK in cellular responses to stress and damage FEBS Lett. 585 2011 952 957
59. D.B. Shackelford, and R.J. Shaw The LKB1-AMPK pathway: metabolism and growth control in tumour suppression Nat. Rev. Cancer 9 2009 563 575
60. S.A. Hawley, D.A. Pan, K.J. Mustard, L. Ross, J. Bain, A.M. Edelman, B.G. Frenguelli, and D.G. Hardie Calmodulin-dependent protein kinase kinase-beta is an alternative upstream kinase for AMP-activated protein kinase Cell Metab. 2 2005 9 19 (Pubitemid 43239821)
61. A. Woods, S.R. Johnstone, K. Dickerson, F.C. Leiper, L.G. Fryer, D. Neumann, U. Schlattner, T. Wallimann, M. Carlson, and D. Carling LKB1 is the upstream kinase in the AMP-activated protein kinase cascade Curr. Biol. 13 2003 2004 2008 (Pubitemid 37425212)
62. B.B. Zhang, G. Zhou, and C. Li AMPK: an emerging drug target for diabetes and the metabolic syndrome Cell Metab. 9 2009 407 416
63. Z. Luo, M. Zang, and W. Guo AMPK as a metabolic tumor suppressor: control of metabolism and cell growth Future Oncol. 6 2010 457 470
64. D.G. Hardie AMP-activated protein kinase as a drug target Annu. Rev. Pharmacol. Toxicol. 47 2007 185 210
65. R. Rattan, R.P. Graham, J.L. Maguire, S. Giri, and V. Shridhar Metformin suppresses ovarian cancer growth and metastasis with enhancement of cisplatin cytotoxicity in vivo Neoplasia 13 2011 483 491
66. G.Z. Rocha, M.M. Dias, E.R. Ropelle, F. Osorio-Costa, F.A. Rossato, A.E. Vercesi, M.J. Saad, and J.B. Carvalheira Metformin Amplifies chemotherapy-induced AMPK activation and Antitumoral growth Clin. Cancer Res. 17 2011 3993 4005
67. K.R. Laderoute, K. Amin, J.M. Calaoagan, M. Knapp, T. Le, J. Orduna, M. Foretz, and B. Viollet 5'-AMP-activated protein kinase (AMPK) is induced by low-oxygen and glucose deprivation conditions found in solid-tumor microenvironments Mol. Cell Biol. 26 2006 5336 5347 (Pubitemid 44036203)
68. D. Tsavachidou-Fenner, N. Tannir, P. Tamboli, W. Liu, D. Petillo, B. Teh, G.B. Mills, and E. Jonasch Gene and protein expression markers of response to combined antiangiogenic and epidermal growth factor targeted therapy in renal cell carcinoma Ann. Oncol. 21 2010 1599 1606
69. J. Carretero, P.P. Medina, R. Blanco, L. Smit, M. Tang, G. Roncador, L. Maestre, E. Conde, F. Lopez-Rios, H.C. Clevers, and M. Sanchez-Cespedes Dysfunctional AMPK activity, signalling through mTOR and survival in response to energetic stress in LKB1-deficient lung cancer Oncogene 26 2007 1616 1625 (Pubitemid 46398737)
70. R.J. Shaw, M. Kosmatka, N. Bardeesy, R.L. Hurley, L.A. Witters, R.A. DePinho, and L.C. Cantley The tumor suppressor LKB1 kinase directly activates AMP-activated kinase and regulates apoptosis in response to energy stress Proc. Natl. Acad. Sci. U S A 101 2004 3329 3335 (Pubitemid 38338195)
71. J.B. Brugarolas, F. Vazquez, A. Reddy, W.R. Sellers, and W.G. Kaelin Jr. TSC2 regulates VEGF through mTOR-dependent and -independent pathways Cancer Cell 4 2003 147 158 (Pubitemid 37045363)
72. D.B. Shackelford, D.S. Vasquez, J. Corbeil, S. Wu, M. Leblanc, C.L. Wu, D.R. Vera, and R.J. Shaw mTOR and HIF-1alpha-mediated tumor metabolism in an LKB1 mouse model of Peutz-Jeghers syndrome Proc. Natl. Acad. Sci. U S A 106 2009 11137 11142
73. M. Sanchez-Cespedes, P. Parrella, M. Esteller, S. Nomoto, B. Trink, J.M. Engles, W.H. Westra, J.G. Herman, and D. Sidransky Inactivation of LKB1/STK11 is a common event in adenocarcinomas of the lung Cancer Res. 62 2002 3659 3662 (Pubitemid 34728843)
74. A.B. Lima, L.T. Macedo, and A.D. Sasse Addition of bevacizumab to chemotherapy in advanced non-small cell lung cancer: a systematic review and meta-analysis PLoS One 6 2011 e22681
75. A.M. Gonzalez-Angulo, and F. Meric-Bernstam Metformin: a therapeutic opportunity in breast cancer Clin. Cancer Res. 16 2010 1695 1700
76. M. Crescenzi, L. Persano, G. Esposito, E. Zulato, L. Borsi, E. Balza, A. Ruol, E. Ancona, S. Indraccolo, and A. Amadori Vandetanib improves anti-tumor effects of L19mTNFalpha in xenograft models of esophageal cancer Clin. Cancer Res. 17 2011 447 458
77. Y. Shaked, A. Ciarrocchi, M. Franco, C.R. Lee, S. Man, A.M. Cheung, D.J. Hicklin, D. Chaplin, F.S. Foster, R. Benezra, and R.S. Kerbel Therapy-induced acute recruitment of circulating endothelial progenitor cells to tumors Science 313 2006 1785 1787 (Pubitemid 44454154)
78. A.A. van der Veldt, M.R. Meijerink, A.J. van den Eertwegh, J.B. Haanen, and E. Boven Choi response criteria for early prediction of clinical outcome in patients with metastatic renal cell cancer treated with sunitinib Br. J. Cancer 102 2010 803 809